NVAX Q4 2018 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-41.2% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$47M-759.1% margin

Net Income

-$49M-805.2% margin

EPS (Diluted)

$-2.58

QoQ Revenue Growth

-20.8%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$46M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$208M

Total Liabilities

$376M

Stockholders' Equity

-$168M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$10M	-41.2%
Gross Profit	$6M	-$39M	+115.6%
Operating Income	-$47M	-$48M	+2.7%
Net Income	-$49M	-$51M	+3.0%